언어 선택

TRAIL R2

TRAIL R2 분자 정보

영어 이름	Tumor necrosis factor receptor superfamily member 10B	시판 약물 수	1
임상 약물 수	10	표적 별명	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
최고 연구 개발 단계	Approved

영어 이름	Tumor necrosis factor receptor superfamily member 10B
표적 별명	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
시판 약물 수	1
임상 약물 수	10
최고 연구 개발 단계	Approved

TRAIL R2 제품 목록

속성
Protein (6)
제품 라이브러리
온라인 (6)
종
Human (4)Mouse (1)Cynomolgus (1)
태그
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)
마커
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)

제품 번호	종	발현 시스템	제품 설명
HOT TR2-H5229	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin
HOT TR2-H5255	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin
HOT TR2-H82E6	Human	HEK293	Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified)
TR2-HF223	Human	HEK293	FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag
TR2-M52H5	Mouse	HEK293	Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag
TR2-C52H7	Cynomolgus	HEK293	Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified)

총 수량6

TRAIL R2분자 배경

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2분자 별명

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Dulanermin (Shanghai GeBaiDe)		Phase 3 Clinical	Shanghai Gebaide Biotechnology Co Ltd	Carcinoma, Non-Small-Cell Lung	상세
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)		Phase 3 Clinical	Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd	Neoplasms	상세
TLY-012	TLY-012	Phase 1 Clinical	Theraly Fibrosis	Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic	상세
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms	상세
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)	CTB-006	Phase 1 Clinical	Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd	Solid tumours	상세
Ozekibart	JCT-205; INBRX-109	Phase 1 Clinical	Inhibrx Inc	Adenocarcinoma	상세
TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Neoplasms	상세
RC-248	RC-248; RC248	Phase 1 Clinical		Solid tumours	상세
IBI-3004	IBI-3004; IBI3004	Phase 1 Clinical		Colorectal Neoplasms; Solid tumours	상세
Oba-01	Oba-01; Oba01	Phase 1 Clinical	Yantai Heyuanaidisi Biomedical Technology Co Ltd	Carcinoma, Non-Small-Cell Lung	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Aponermin		Approved	Beijing Shadong Biotech Co Ltd	沙艾特, Shaite	Mainland China	Multiple Myeloma	Wuhan Hiteck Biological Pharma Co Ltd	2023-11-02	Multiple Myeloma	상세